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Macrophage activation seems to be a feature of chronic liver diseases. Picolinic acid (PA) as a macrophage secondary signal
causes the activation of interferon-gamma- (IFN-γ-) prime macrophage and triggers cytokine-driven inﬂammatory reactions.
The rationale for seeking increased PA formation in chronic viral hepatitis is based on the involvement of activated macrophages
in chronic viral hepatitis-associated inﬂammation. The aim of this study was to determine serum PA levels in patients with chronic
hepatitis C infection, taking into account the presence of diabetes. We assessed PA and high-sensitivity C-reactive protein (hsCRP)
as a marker of inﬂammation in 51 patients with chronic hepatitis C infection (CHC), both with and without diabetes and 40
controls. Compared with the controls, the patients with CHC showed a signiﬁcant increase in plasma concentrations of PA and
hsCRP (P<0.01 and P<0.05, resp.). The values of PA and hsCRP were more elevated in patients with diabetes than without
diabetes (both P<0.01). The positive relationships were between PA and hsCRP levels (P<0.05) and the presence of diabetes
(P<0.001). We documented that signiﬁcant elevation in serum PA levels is associated with diabetes prevalence and increased
inﬂammatory response reﬂected in hsCRP levels in CHC patients.
1.Introduction
Hepatitis C virus (HCV) infection has been associated with
various extrahepatic manifestations, and diabetes mellitus
is one of these. Diabetes in patients with chronic hepatitis
C infection (CHC) has unique and complex pathogenesis,
which distinguishes this metabolic disorder from type 2
diabetesmellitus.Inthisregard,ahighprevalenceofdiabetes
has been reported in HCV-infected patients in comparison
with other liver diseases [1–3]. Mehta et al. [4]h a v er e p o rt e d
that preexisting HCV infection may increase the risk of
type 2 diabetes mellitus in patients with recognized diabetes
risk factors. The mechanisms by which chronic hepatitis
C infection induces increased insulin resistance and the
risk for development of diabetes have not been completely
clariﬁed. It has been observed that type 2 diabetes mellitus
occurs in the early stages of liver disease [5]. In the light of
these observations, the mechanism through which chronic
hepatitis C infection is associated with insulin resistance may
involve direct viral eﬀects, proinﬂammatory cytokines, and
suppressors of cytokine signaling (reviewed in [6]).
In particular, inﬂammation has been hypothesized to
underlie not only the pathogenesis of the diabetes but
also its association with cardiovascular diseases [7–12]. The
prototypic marker of inﬂammation is C-reactive protein
(CRP). Numerous studies, especially in normal individuals,
have shown that CRP levels in the highest quantile predict
cardiovascular events [11, 12]. Similarly, both white blood
cell (WBC) count and erythrocyte sedimentation rate (ESR)
have been associated with cardiovascular risk [13, 14].
There is also evidence supporting the suggestion that CRP
levels are increased in diabetes [7, 15, 16]. Moreover,
accumulated evidence suggests that HCV increases the risk
of atherosclerotic cardiovascular disease by causing insulin
resistance, diabetes, and inﬂammation [3].2 Mediators of Inﬂammation
Tryptophan (TRP) exceeding basal requirement for
protein synthesis is oxidized via indole-ring cleavage
through the kynurenine pathway, consisting of several enzy-
matic reactions leading to 2-amino 3-carboxymuconate 6-
semialdehyde (ACMS) [17]. ACMS can be decarboxylated
to 2-aminomuconate 6-semialdehyde (AMS) by the enzyme
ACMS decarboxylase (ACMSD), or it can undergo sponta-
neous pyridine ring closure to form quinolinate, an essential
precursor for de novo NAD synthesis. AMS can be converted
nonenzymatically to picolinic acid (PA) or routed to the
citric acid cycle via the glutarate pathway. TRP catabolism,
initiated by indoleamine 2,3-dioxygenase (IDO), leads to the
production of biologically active molecules. Interferon-γ has
been shown to be a potent stimulating cytokine for IDO
in vitro. Similarly in vivo, a decrease in serum tryptophan
and an increase in kynurenine in parallel were exhibited,
indicating an enhanced degradation of tryptophan, while
the cellular immune system is activated. In particular, the
ratio of kynurenine to tryptophan (KYN/TRP) seems to
be a sensitive indicator for interferon-γ-induced tryptophan
degradation (reviewed in [18]).
The role of the tryptophan, particularly during inﬂam-
mation, is just beginning to be appreciated, and a great deal
of recent research has focused on the eﬀects of tryptophan
catabolites on eﬀectors cell function [19]. TRP catabolites,
biologically active molecules [20], represent a relatively
newly identiﬁed class of stimuli, which diﬀer from classical
immunological stimuli because of their capability to signal
to the macrophages through mechanisms that do not require
a cell-surface receptor. Among them, picolinic acid (PA),
a terminal metabolite of tryptophan degradation detected
in vivo in human sepsis [21] and in the serum of patients
with liver cirrhosis [22], is capable of triggering mouse
macrophages production of a number of inﬂammatory gene
products, such as reactive nitrogen intermediates [23]a n d
cytokine [24]. Furthermore, TRP-derived catabolites have
been detected in vivo in patients with viral infections,
malignant and inﬂammatory diseases [25–27].
The results of numerous studies strongly suggest that
macrophage activation seems to be a feature of chronic liver
diseases [28–30]. However, other studies have suggested a
role for TRP-derived catabolizes in macrophages activation
[21, 23]. The rationale for seeking increased PA formation
in chronic viral hepatitis is based on the involvement of
activated macrophages in chronic viral hepatitis-associated
inﬂammation. Elevated formation of PA in patients with
chronic hepatitis C infection might be expected due to
enhanced TRP breakdown demonstrated in inﬂammatory
reactions. The aim of this study was to determine serum PA
levels in patients with chronic hepatitis C infection, taking
into account the presence of diabetes.
2. Patientsand Methods
2.1. Patients and Study Design. This study was performed in
51 patients with chronic hepatitis C infection (CHC) admit-
ted to the Clinic of Infectious Diseases, Liver Diseases and
Acquired Immune Deﬁciency for evaluation. The control
groupconsistedofhealthyblooddonorswithnormalamino-
transferases, normal blood counts, and negative markers for
virus hepatitis and HIV (23 males/17 females, median age
32.5 years, range 19–65 years). No statistically signiﬁcant
diﬀerence between the CHC patients and healthy controls
in female/male ratio (P = 0.51) was found. There was a
signiﬁcant diﬀerence in age, but PA level was not age related
in neither the controls (r = 0.14, P<0.21) nor the CHC
patients (r = 0.17, P<0.34). Clinical and biochemical char-
acteristicsofthestudygrouparereportedindetailinTable 1.
The exclusion criteria were as follows: (1) liver cirrhosis;
(2) conditions other than diabetes and HCV infection that
could inﬂuence either serum glucose levels: premenopausal
women; alcohol consumption >40g/day; treatment with
steroid or no steroidal anti-inﬂammatory drugs, except
aspirin; concomitant infection; chronic diseases other than
diabetes; (3) type 1 diabetes (history of diabetic ketoacidosis
or age <30 years with insulin requirement) and secondary
diabetes due to chronic pancreatitis or pancreatic tumor.
Liver cirrhosis was ruled out by liver biopsy performed
within 18 months before inclusion (compensated patients)
or by typical clinical features such as signs of portal
hypertension (splenomegaly, ascites, and esophageal varies),
hematologic evidence of hypersplenism, or biochemical
evidence of hepatocellular failure.
The diagnosis of chronic hepatitis C infection was based
on persistently increased alanine aminotransferase values,
anti-HCV and HCV-RNA positivity, and liver histology
features.TheHCVinﬂammationwasconﬁrmedbymeasure-
ment of HCV Ab and HCV RNA in the serum, using the
EIA methods and RT PCR-Cobas Amplicor Roche methods,
respectively. For the anti-HCV-positive patients with normal
aminotransferase levels and no liver biopsy, we ensured that
aminotransferase levels and liver function tests results were
persistently normal.
Patients were divided in two groups according to their
HCV antibody status and the presence of diabetes: anti-
HCV-positive diabetic patients (n = 22) and anti-HCV-
positive nondiabetic patients (n = 29). Diabetes was deﬁned
on the basis of a history of therapy with oral hypoglycemic
agents or insulin at the time of inclusion. Based on the
clinical information, all diabetic patients in this study were
a s s u m e dt oh a v et y p e2d i a b e t e sm e l l i t u s .
We also evaluated 34 CHC patients with cirrhosis and
an additional group of 12 patients with chronic hepatitis
B infection. The diagnosis of liver cirrhosis was based on
clinical, laboratory, and ultrasonographic ﬁndings or histo-
logical criteria. The Child-Pugh score was used to assess the
severity of liver disease. Three biochemical variables [serum
albumin, bilirubin, and prothrombin time (international
normalized ratio, INR)] in addition to the two clinical
characteristics (presence or absence of ascites and clinical
signs of encephalopathy) determine the Child-Pugh score.
Patients were scored as follows: 5–6 as class (group) A,
7–9 as class (group) B, and 10–15 as class (group) C.
The HBV infection was conﬁrmed by measurement of the
following infection markers in the blood serum: HbsAg,
HbeAg, HbcAb, HbeAb-MEIA methods, Abbotts IMX, and
HBV DNA-Digene Hybrid Capture.Mediators of Inﬂammation 3
Table 1: Clinical and biochemical characteristics of patients with chronic hepatitis C infection (CHC) and healthy controls.
Healthy
Controls CHC patients Cirrhotic CHC
patients
(n)4 0 5 1 3 4
Male:female ratio 23:17 22:29 14:10
Age (years) 32.5 (19–65) 46∗ (18–65) 43 (26–70)
BMI (kg/m2) 28 (22–33) 25.6 (22–31) —
Diabetes mellitus (%) — 43% —
ALT (U/L) 24 (20–28) 93∗∗(10–392) 47∗∗ (16–79)
AST (U/L) 27 (23–30) 68∗∗(12–272) 79∗∗ (19–150)
γ-GT (U/L) 26 (25–28) 62.5∗ (9.0–321) 92∗∗ (78–106)
Total cholesterol (mg/dL) 188 (140–200) 160 (154–209) 140∗ (130–203)
LDL cholesterol (mg/dL) 116 (80–130) 110 (78–141) 92 (80–135)
HDL cholesterol (mg/dL) 60 (35–80) 43 (30–52) 40 (30–75)
Triglycerides (mg/dL) 76 (35–150) 84 (76–183) 78 (30–190)
Albumin (g/L) 45 (36–57) 41 (39–48) 30∗ (16–45)
hsCRP (mg/L) 1.2 (0.1–4.8) 3.5∗(0.22–4.45) 4.9∗∗ (3.5–10.5)
Data reported as median (range). Statistical signiﬁcance: ∗P<0.05; ∗∗P<0.01 versus healthy controls. AST, aspartate aminotransferase; ALT, alanine
aminotransferase; γGT, gamma glutamyltransferase; hsCRP, high-sensitivity C-reactive protein.
The consent of the Bioethics Committee of the Wroclaw
Medical University was obtained, and all patients were
informed about the character of analyses made. Studies were
conducted in compliance with the ethical standards formu-
lated in the Helsinki Declaration of 1975 (revised in 1983).
2.2. Biochemical Analysis. Peripheral venous blood from
fasted healthy subjects and fasted CHC patients was col-
lected in separate tubes, one containing the anticoagulant
ethylenediamine tetraacetic acid and the other without
serum anticoagulant. The blood was allowed to clot for
30min at 25◦C and centrifuged at 2000×gf o r1 5 m i na t
room temperature, and the serum was then separated and
aliquotedintotubesforstorage.Thetubeswerestoredfrozen
at −80◦C until they were used to study diﬀerent parameters.
A wide panel of biochemical and hematological param-
eters were evaluated by standard automated techniques.
Serum CRP levels were determined with a high-sensitivity
nephelometric method using the Beckman Image Immuno-
chemistry system (Beckman Instruments, Fullerton, CA),
which has a minimum level of detection of 0.2mg/L. The
intra- and interassay coeﬃcients of variation for measure-
ments of CRP were 2.7% and 3.0%, respectively.
2.3. Determination of Tryptophan (TRP), Kynurenine (KYN),
and Picolinic Acid (PA). The concentrations of serum TRP,
KYN, and PA in patients with CHC (n = 51) were deter-
mined by high-performance liquid chromatography (HPLC)
(22), and the content ratios of KYN to TRP (KYN/TRP)
were calculated. In brief, a Waters Model 2690 (Milford,
MA, USA) was used. Sample injection was controlled by
a Millennium 32 data system, and a 100l loading loop
was used. Tryptophan was detected with a ﬂuorescence
detector (Waters 474 scanning ﬂuorescence detector) at an
excitation wavelength of 285nm and an emission wavelength
of 360nm; kynurenine was detected by a UV detector
(Waters2487dualdeltaabsorbancedetector)atawavelength
of 360nm, and picolinic acid was detected by the same
UV detector at a wavelength of 265nm. An array detector
(Waters 996 photodiode array detector) was used for the
identiﬁcation of the peaks. To control the setup and for peak
quantiﬁcation, Borwin and MS Excel software was used.
Samples were prepared as described previously [22].
Brieﬂy,beforeeachHPLCanalysis,weusedacidprecipitation
to dissociate the putative PA-protein complexes and to
extract the samples. Every sample was spiked with methyl-
DL tryptophan (as an internal standard) before the acid
precipitation. Blood serum was adjusted to a ﬁnal con-
centration of cold 2% perchloric acid and kept on ice for
30min. Samples were centrifuged at 13000g for 6min at
room temperature to precipitate and separate the protein.
Supernatantwasneutralizedbyadjustingto0.4Mpotassium
hydroxide, ﬁltered through a 0.45μm ﬁlter (13mm GHP
0.45mm Minispike from Waters), and analyzed by HPLC.
For chromatographic separation, we used the Symmetry
Shield RP18 column (Waters) and the Symmetry Shield
RP18 precolumn (Waters) to protect the column. After a
chromatographic session was completed, once per day the
system was rinsed with a gradient to/from pure methanol,
and the precolumn was replaced. The identiﬁcation of
tryptophan catabolites was achieved by comparing the
retention times and spectral data (obtained by diode-
array detection) with the standard and by spiking the
samples with PA, KYN, and TRP. For quantiﬁcation, plasma
samples were spiked with standard. Calibration curves were
ﬁtted by linear least-square regression and correlated with
the concentration of methyl-DL tryptophan. Finally, the
kynurenine-to-tryptophan (KYN/TRP) ratio was calculated
dividing kynurenine concentrations (μmol/L) by tryptophan
concentrations (μmol/L).4 Mediators of Inﬂammation
The precision of the method was estimated by measuring
the PA at four diﬀerent concentrations [22]. The intraday
and interday variations were determined by spiking with PA
in triplicate runs 2 times within 1 day and in at least 1 run
per day for 6 days. Coeﬃcient of variation (CV) served as the
indicator of the precision. Intraday and interday CV values
were within 2.5%. The CV values obtained in this study are
similar to those reported previously [22].
2.4. Statistical Analysis. Results are expressed as median
(25th percentile–75th percentile). Frequency data were com-
pared using the χ2 test or the Fischer’s exact test when nec-
essary. Because many of the variables analyzed did not have
a normal distribution as determined by the Kolmogorov-
Smirnov test, nonparametric tests were used for comparison
of data. The Mann-Whitney U test and the Kruskal-
Wallis test were used to analyze diﬀerences among two or
more groups, respectively. Multiple regression analysis was
conducted by a stepwise model (with P<0.05 as an entrance
criterion and P>0.1asaremovalcriterion).Variablesfound
to signiﬁcantly correlate with PA in bivariate analysis were
introduced into the model as explanatory variables (WBC,
hsCRP, and the presence of diabetes in all subjects or in
diabetic CHC patients). Regression analysis to determine
signiﬁcant correlations among diﬀerent parameters was per-
formedusingtheSpearmancorrelationcoeﬃcient.Statistical
signiﬁcance was established at P<0.05.
3. Results
3.1. TRP, KYN, and PA Serum Concentrations in Patients with
Chronic Hepatitis C Infection (CHC) and Healthy Controls.
We analyzed 51 patients (23 males/17 females, median
age 46 years, range 18–65 years) with chronic hepatitis C
infection (CHC). The distribution of the stages of liver
cirrhosis as deﬁned according to the Child-Pugh score and
measurements of tryptophan (TRP) and catabolites serum
concentrationsarepresentedinFigure 1.TRPandcatabolites
were also checked for correlations with selected biochemical
markers of liver function (albumin, prothrombin ratio, and
bilirubin concentration) and injury (aminotransferases).
TheconcentrationofTRPwasmeasuredinall51patients
with CHC with a median of 65.8μmol/L (range 53.8–
77.4μmol/L) (Figure 1(a)). In healthy controls, the serum
TRP was similar to those in healthy controls in other studies
[31]. Serum TRP in CHC patients without cirrhosis was
only slightly reduced compared with that in other groups.
However, TRP levels were unchanged in CHC patients
with cirrhosis (n = 34) (Figure 1(a)). Unexpectedly, all
CHC patients had lower kynurenine levels in their serum
than healthy controls (Figure 1(b)). The kynurenine to
tryptophan (KYN/TRP) ratio in CHC patients was slightly
lower than that of the controls, but this diﬀerence was
not statistically signiﬁcant (0.044 ± 0.02 versus 0.046 ±
0.05; P = 0.11). Serum KYN levels were signiﬁcantly
lower in CHC patients with cirrhosis than those measured
in healthy controls. However, in patients with Child-Pugh
class A cirrhosis, the serum KYN was similar to that in
healthy controls (Figure 1(b)). The relatively small number
of subjects in this group is insuﬃcient to draw a meaningful
conclusion (n = 9). There was no signiﬁcant diﬀerence in
KYN levels between the Child-Pugh class A and Child-Pugh
class C cirrhotic patients. The peculiarity of CHC patients is
the reduction in serum TRP associated with reduced serum
KYNlevels.Theimportanceofsuchmetabolicchangesinthe
overall clinical picture remains to be studied in detail.
Picolinic acid (PA) serum concentrations were signiﬁ-
cantly higher in CHC patients than in healthy controls (con-
trols median 0.2μmol/L range 0.2–1.8μmol/L, P<0.01).
Serum PA concentrations were higher in Child-Pugh class
A to class C cirrhotic patients (n = 34, median 2.1μmol/L,
range 0.2–29.2μmol/L) than in patients without cirrhosis
(n = 51, median 1.7μmol/L, range 0.2–6.7μmol/L), but this
diﬀerence was not statistically signiﬁcant (Figure 1(c)). The
levels of serum PA in all cirrhotic patients were higher than
those of healthy controls, and this diﬀerence was statistically
signiﬁcant(P<0.01)(Figure 1(c)).ThelevelsofserumPAin
patients with Child-Pugh class C cirrhosis were higher than
those in Child-Pugh class A cirrhosis, but this diﬀerence was
not statistically signiﬁcant (P = 0.17) (Figure 1(c)). There
was no statistically signiﬁcant correlation between PA levels
and the Child-Pugh score in cirrhotic patients.
Correlation analysis of TRP, KYN, PA, and selected
inﬂammatory markers revealed only a tendency toward an
extremely weak but signiﬁcant correlation between PA and
hsCRP in CHC patients (r = 0.23, P<0.05). No correlation
was found between TRP, KYN, PA and biochemical markers
of liver function (albumin, prothrombin ratio, and bilirubin
concentration) and injury (aminotransferases). We failed to
ﬁnd any relation between the circulating levels of PA and
TRP, KYN, or KYN/TRP ratio.
3.2. Association between Serum Levels of PA and Viral Etiology
of Hepatitis. Diﬀerences in serum TRP and KYN were not
signiﬁcant in both chronic hepatitis C and chronic hepatitis
B infection. Unfortunately, eﬀorts to conduct studies in
patients with chronic hepatitis B have been hampered by
the fact that the majority of chronically infected persons do
not develop symptoms and therefore do not seek medical
attention; consequently, the numbers included in the case
series have been small. Although we could not ﬁnd an
association between the serum concentration of PA and
viral etiology of hepatitis (Table 2), PA serum levels were
considerably lower in the group with chronic hepatitis
B infection (n = 12, median 1.02μmol/L, range 0.2–
5.0μmol/L) than in the group with chronic hepatitis C
infection. These results are based on a small number of
subjects, so the lower PA serum levels in this group should
be viewed with caution.
3.2.1. Clinical and Biochemical Characteristics of Patients with
Chronic Hepatitis C Infection (CHC) according to the Presence
of Diabetes. The demographic, biochemical, and clinical
characteristics of healthy controls and CHC patients both
with and without diabetes are shown in Table 3. Distribution
of sex was similar among groups. By design, glucose andMediators of Inﬂammation 5
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Figure 1: (a) Tryptophan (TRP) serum concentrations in 85 patients with chronic hepatitis C infection (CHC), according to child’s stage of
cirrhosis, and in a control group of 40 healthy blood donors. P values are given in the table. Comparisons between subgroups are illustrated
with box plot graphics, where the dotted line indicates the median per group, the box represents 50% of the values, and horizontal lines show
minimum and maximum values of the calculated nonoutlier values; asterisks and open circles indicate outlier values. (b) Kynurenine (KYN)
serum concentrations decrease with the stage of liver cirrhosis in patients with CHC. However, in patients with Child-Pugh class A cirrhosis,
the serum KYN was similar to those in healthy controls. P values are given in the table. (c) Picolinic acid (PA) serum concentrations increase
with the stage of liver cirrhosis in patients with CHC. P values are given in the table.6 Mediators of Inﬂammation
Table 2: Serum tryptophan (TRP), kynurenine (KYN), and picolinic acid (PA) in patients with chronic viral hepatitis.
TRP (μmol/L) KYN (μmol/L) PA (μmol/L)
Healthy controls
(n = 40) 79.8 (61.2–102.8) 3.6 (2.2–5.25) 0.2 (0.2–1.81)
Chronic hepatitis C
infection (n = 51) 65.8 (53.8–77.4) 3.0 (0.5–5.0) 1.7∗(0.2–6.7)
Chronic hepatitis B
infection (n = 12) 61.5 (48.4–74.2) 2.6 (0.44–4.1) 1.02∗(0.2–5.0)
Signiﬁcance levels between groups: ∗P<0.05 versus healthy controls.
HbA1c levelswerehigherinCHCpatientswithdiabetesthan
in CHC patients without diabetes, and aminotransferase
levelswerehigherinCHCpatientswithandwithoutdiabetes
than in the healthy controls.
PA levels in CHC patients with diabetes were higher
than those in the other groups (P<0.01) (Table 3). In
addition, when patients with normal aminotransferases were
examined, the diﬀerences remained statistically signiﬁcant
(data not shown). However, PA levels in nondiabetic CHC
patients were similar to those in the healthy controls.
Compared with the healthy controls, CHC patients with
diabetes showed a signiﬁcant increase in serum concen-
trations of high-sensitivity C-reactive protein (hsCRP) and
white blood cell (WBC) counts (Table 3). The levels of
serum hsCRP in diabetic CHC patients were higher than
those of the nondiabetic patients, and this diﬀerence was
statistically signiﬁcant (P<0.01). There were no diﬀerences
in platelet (PLT) counts and erythrocyte sedimentation rate
(ESR) between patients and healthy controls (Table 3).
The association study revealed only a tendency toward
an extremely weak but signiﬁcant correlation between PA
and WBC in CHC patients with diabetes (r = 0.25, P<
0.05). However, a moderate correlation between PA levels
and hsCRP was observed among the diabetic CHC patients
(r = 0.43, P<0.05).
Using serum PA level of 3.14μmol/L as a cut-oﬀ value,
the patients with CHC were divided into two groups (high
or low levels of PA). The relationship between PA (high or
low levels) and the other variables considered in the study in
patients of the whole group (CHC patients with and without
diabetes) and CHC patients without diabetes is shown in
Table 4. In the whole group of patients, PA was related to
the presence of diabetes and high levels of hsCRP (Table 4).
However, when diabetic CHC patients were excluded, the
relationship between PA and hsCRP disappeared (Table 4).
3.3. Multiple Regression Analysis of PA Associations. We
found that from among the variables (entered into the
model, that is, WBC, hsCRP, and the presence of diabetes),
only hsCRP exerted an independent eﬀect on PA level in
diabetic CHC patients. This index alone accounted for 38%
of PA variance (coeﬃcient of determination: R2 = 0.38;
multiple correlation coeﬃcient: Rm = 0.62; signiﬁcance of
the model: P<0.001). For all CHC patients, hsCRP and the
presence of diabetes were found to aﬀect PA serum level. The
regression model with these 2 variables explained 60% of PA
variance (R2 = 0.60; Rm = 0.76, P<0.001).
4. Discussion
To our knowledge, this is the ﬁrst report of elevated PA
concentrations in patients with chronic hepatitis C infection
(CHC) in which a relationship of PA to the inﬂammatory
response has been demonstrated. Previous studies demon-
strated increased levels of picolinic acid in the serum of
patients with chronic liver diseases [22], but in these studies
confounding factors such as age distribution, severity of liver
damage (cirrhosis versus chronic hepatitis), or the presence
of diabetes have not been taken into account. PA triggers
cytokine-driven inﬂammatory reactions in vitro. The net
eﬀects on markers of inﬂammation in CHC patients are
unknown.
In the present study, we have examined the relationship
between KYN pathway metabolism and inﬂammation by
comparing both hsCRP and white blood cell count in
CHC patients showing high levels of PA in the presence of
low circulating KYN concentrations. After considering the
confounding factors mentioned above, we provide evidence
that the connection between PA and chronic inﬂammatory
state is initiated at early stages of chronic viral hepatitis.
Inﬂammation is a major component of the pathogenesis
of chronic HCV infection [32, 33]. In clinical studies,
signiﬁcant decreases in serum TRP concentrations have been
reportedinpatientswithchronicinﬂammatorydiseasessuch
as HIV infection, malaria, and malignant and inﬂammatory
bowel diseases (reviewed in [34]). Enhanced breakdown
of TRP leading to the production of biologically active
metabolites has been demonstrated in vivo under inﬂam-
matory conditions, during the rejection of transplanted
tumors or in cancer patients treated with interferon-gamma
(IFN-γ)[ 35], and the TRP catabolite, picolinic acid (PA),
was found in the serum of patients with liver cirrhosis
[22]. The present ﬁnding that PA accumulation coexists
with decreased levels of TRP and the KYN/TRP ratio
supports the contention that ﬂux through the kynurenine
pathway is reduced in CHC patients. The most plausible
explanation for the results obtained is that downstream
catabolism of quinolinic acid is reduced, thereby providing
higher levels of the intermediate aminocarboxymuconate-
semialdehyde (ACMS) for PA synthesis. Picolinic acid as
a macrophage secondary signal causes the activation of
IFN-γ-prime macrophage [23] and triggers cytokine-driven
inﬂammatory reactions in vitro. On the other hand, the
recruitment of circulating leukocytes to an inﬂammatory
site in response to stimuli such as the hepatitis C virus isMediators of Inﬂammation 7
Table 3: Clinical and biochemical characteristics of patients with chronic hepatitis C infection (CHC) according to the presence of diabetes.
Healthy controls CHC patients with
diabetes
CHC patients
without diabetes
(n)4 0 2 2 2 9
Male:female ratio 23:17 10:12 12:17
Age (years) 32 (19–65) 46 (21–65) 45 (18–60)
BMI (kg/m2) 28 (22–33) 27 (23–31) 25.8 (22–29)
Glucose (mmol/L) 4.6 (4.0–5.2) 7.6∗∗+ (5.7–9.5) 5.2 (4.7–5.7)
HbA1c(%) — 7.8+ (5.0–9.8) 5.4 (5.0–6.0)
ALT (U/L) 24 (20–28) 86∗∗ (10–392) 74∗ (20–144)
AST (U/L) 27 (23–30) 68∗ (12–272) 53∗ (20–97)
Albumin (g/L) 45 (36–57) 43 (39–44) 45 (43–48)
PA (μmol/L) 0.2 (0.2–1.81) 1.9∗∗+(0.8–6.7) 0.32 (0.2–1.5)
hsCRP (mg/L) 1.2 (0.1–4.8) 3.14∗+(0.36–4.45) 1.51 (0.22–1.9)
ESR (mm/h) 6 (5–7) 8 (3.5–22) 6 (5–7)
PLT (×109/L) 200 (150–220) 205 (158–240) 207 (161–242)
WBC (×109/L) 4.6 (4.2–5.1) 6.7∗(5.1–8.8) 5.3 (4.5–7.4)
Data reported as median (range). Signiﬁcance levels between groups: ∗P<0.05; ∗∗P<0.01 versus healthy controls; +P<0.01 versus CHC patients without
diabetes. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; PA, picolinic acid;
P L T ,p l a t e l e t ;W B C ,w h i t eb l o o dc e l l s .
Table 4: Comparison between the patients of the whole group (CHC patients with and without diabetes) and nondiabetes CHC patients
classiﬁed according to the ﬁnding of low (≤3.14μmol/L) and high (>3.14μmol/L) levels of picolinic acid (PA).
CHC patients (n = 51) CHC patients without diabetes (n = 29)
PA ≤3.14μmol/L PA>3.14μmol/L PA≤3.14μmol/L PA>3.14μmol/L
n (%) 28 (54) 23 (46) 16 (56) 13 (44)
Age (years) 40 (18–52) 42 (26–65) 42 (21–60) 43 (18–58)
BMI (kg/m2) 24.9 (22–31) 25.7 (23–27) 24.8 (22–28) 26 (23–29)
hsCRP (mg/L) 2.4 (0.51–2.9) 3.7+ (0.22–4.45) 0.88 (0.25–1.9) 1.0 (0.22–1.75)
HbA1c(%) 5.8 (5.0–7.9) 7.0++ (5.4–9.8) — —
Diabetes n (%) 5 (10) 17 (33)++ ——
Total cholesterol
(mg/dL) 165 (154–198) 178.2 (161–209) 173.8 (161–196) 168.5 (164–209)
LDL cholesterol
(mg/dL) 84 (78–102) 86 (80–141) 102 (96–139) 98 (95–141)
HDL cholesterol
(mg/dL) 37 (33–49) 36 (30–52) 37 (33.0–49.5) 38.6 (34–52)
Triglycerides
(mg/dL) 85 (76–150) 87 (80–183) 84 (76–148) 81 (79–137)
ALT (U/L) 43 (10–319) 57 (10–392) 42 (20–137) 53.7 (20–144)
AST (U/L) 35 (12–143) 45 (16–272) 33.5 (20–87) 35 (20–97)
γ-GT (U/L) 29 (9.0–101) 34 (12–321) 28.7 (10.0–99.7) 32.7 (14–309)
Signiﬁcance between groups: +P<0.05; ++P<0.01 by multivariate analysis. AST, aspartate aminotransferase; ALT, alanine aminotransferase; γGT, gamma
glutamyltransferase; hsCRP, high-sensitivity C-reactive protein.
a crucial step in the development of chronic inﬂammatory
responses. In these conditions, extravasation of circulating
leukocytes requires communication with vascular endothe-
lial cells that in turn depends on an interrelated network
of events involving the proinﬂammatory cytokines (i.e.,
interleukin [IL]-1β, IL-6, and tumor necrosis factor [TNF]-
α), adhesion molecules, and chemokines (notably MIP-1-α
and MIP-1-β). The experiments in cell showed that PA is
an activator of the inﬂammatory chemokines macrophage-
inﬂammatory-protein- (MIP-) 1-α and MIP-1-β mRNA
expression macrophages through an o v oprotein synthesis-
dependent process [24]. Thus, the very weak correlation
between PA levels and inﬂammatory marker C-reactive
protein (hsCRP) may suggest an indirect contribution of
PA to the maintenance of the inﬂammatory milieu through
other mediators. Finally, the values of PA in CHC patients8 Mediators of Inﬂammation
and normal aminotransferases suggest that PA might have
a role in the early stages of chronic viral hepatitis by
amplifying the chronic inﬂammatory state already caused by
the hepatitis C virus [32, 33].
The association between tryptophan content and dia-
betes is supported by the observation that tryptophan levels
are reduced in age-related metabolic disorders [36]. The
speciﬁc mechanisms that could lead to PA enhancement in
CHC patients with diabetes remain to be explained. It is
possible to speculate that elevated levels of PA may occur as a
result of increased activity of the enzyme responsible for the
synthesis of PA. ACMSD (picolinate carboxylase, 2-amino
3-carboxymuconate 6-semialdehyde (ACMS) decarboxylase;
ACMSD) is a key enzyme directing kynurenine pathway
metabolism towards PA production and is mainly present
in liver, kidney, and brain tissue. One study showed that
in liver of streptozotocin-induced diabetic rats, hepatic
ACMSD activity is increased markedly, and insulin injection
suppresses this elevation [37]. These studies demonstrated
that changes in ACMSD activity are reﬂected by serum PA
levels. Finally, our results showed that diabetes but not HCV
infection was independently related to PA in patients with
chronic hepatitis C infection.
Accumulating evidence suggests that chronic hepatitis C
virus infection increases the risk of atherosclerotic cardio-
vascular disease by causing insulin resistance and diabetes
[1, 3, 38]. Some research has suggested that hepatitis C virus
may also trigger the release of proinﬂammatory cytokines
such as TNF-α,I L - 6 ,I L - 1 β, and inﬂammatory CRP [39,
40]. The results of general population-based studies have
also demonstrated a relationship between hepatitis C virus
persistence and carotid atherosclerotic plaques and intima-
media thickness [41]. Interestingly, this recent research
suggests that active macrophage inﬁltration into the arterial
wall induces the development of an early atherosclerotic
lesion [42]. On the other hand, as we mentioned above,
PA is capable of activating macrophages and inducing the
expression of the inﬂammatory chemokines MIP-1α and
MIP-1β belong to the β-chemokines family, which plays a
key role in the recruitment of mononuclear cells (monocytes
and T lymphocytes) into atherosclerotic lesions. Together,
our observations show that the simultaneous elevation of PA
and hsCRP levels in CHC patients with diabetes suggest that
their local tissue production is linked. This is in accordance
withexperimental datashowing overexpressionin plaquesof
both β-chemokines [43]a sw e l la sC R P[ 44]a n dm a yb ed u e
to global activation of cells that synthesize and secrete these
molecules. Even if the correlation between PA and WBC
was extremely weak, we demonstrated clear association with
inﬂammatory CRP. Finally, our results show that the eleva-
tion of PA was dependent on inﬂammation status because in
diabetic CHC patients with normal hsCRP concentrations,
PA level was not signiﬁcantly elevated in comparison with
healthycontrols(datanotshown).AlthoughCRPcanmerely
be a marker of an underlying inﬂammatory process, it is
possible that CRP may be directly involved in the patho-
genesis of inﬂammation/atherosclerosis [45]. In this context,
the association between picolinic acid and the presence of
inﬂammation in CHC patients with diabetes could represent
one of the mechanisms involved in atherosclerotic process in
this population. However, the mechanisms underlying this
association are still not completely clariﬁed.
Some limitations of the current study should be con-
sidered. Firstly, the small set of 51 patients included in this
study may have resulted in limited power to discriminate
between categories and levels of exposure. Secondly, the
part of our patients, categorized as “CHC patients without
diabetes” may have diabetes without symptoms, and many
of them may develop diabetes in the future. Finally, because
of its cross-sectional nature, this study is limited in terms
of deriving mechanistic conclusions; however, results of this
study are hypothesis generating and provide insights into the
relationship between PA levels and inﬂammatory response
and the presence of diabetes in patients with CHC.
In conclusion, we have documented signiﬁcant elevation
in serum levels of PA in patients with CHC. In addition,
circulating PA was associated with inﬂammatory marker
CRP and the presence of diabetes, but not with markers
of liver injury aminotransferases. In summary, our results
provide further evidence for the presence of high levels of
hsCRP in CHC patients with diabetes, and we propose a role
for PA in this context. The results of our study should be
interpreted as trends to be conﬁrmed by further studies with
larger sample size.
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